Schedules and doses used in regimens for younger patients
| Trial . | Regimen . | n . | Mean/median age, y (range) . | Stage III/IV, % . | IPS ≥4, % . | CR/Cru, % . | PFS, % (y) . | OS, % (y) . | TRM, % . | Secondary malignancies, % . |
|---|---|---|---|---|---|---|---|---|---|---|
| HD200036 | ABVD ×6 | 99 | 32 (NA) | 67 | 30* | 84 | 69 (10) | 85 (10) | 0 | 1 |
| escBEACOPP ×4, then BEACOPP ×2 | 98 | 29 (NA) | 69 | 43* | 91 | 75 (10) | 84 (10) | 2 | 6 | |
| COPPEBVCAD ×6 | 98 | 33 (NA) | 71 | 44* | 83 | 76 (10) | 86 (10) | 0 | 6 | |
| GHSG HD1235 | escBEACOPP ×8 +RT | 392 | 36 (16-65) | 83 | 15 | 93 | 89 (5) | 92 (5) | 2 | 3.6 |
| escBEACOPP ×8 −RT | 395 | 35 (16-65) | 84 | 18 | 93 | 87 (5) | 91 (5) | 2.8 | 2.3 | |
| escBEACOPP ×4, then BEACOPP ×4 +RT | 393 | 36 (16-65) | 83 | 19 | 92 | 87 (5) | 91 (5) | 4.3 | 2.5 | |
| escBEACOPP ×4, then BEACOPP ×4 −RT | 394 | 35 (16-65) | 85 | 15 | 90 | 84 (5) | 90 (5) | 2.5 | 0.8 | |
| Viviani et al37 | ABVD ×6-8, then re-induction and HDT/ASCT if less than CR or PD | 168 | NR | NR | 53* | 76 | 73 (7) | 84 (7) | 1 | 1 |
| escBEACOPP ×4, then BEACOPP ×4 then re-induction and HDT/ASCT if less than CR or PD | 163 | NR | NR | 53* | 81 | 85 (7) | 89 (7) | 2 | 1 | |
| GHSG HD154 | escBEACOPP ×8 | 705 | 33 (18-60) | 83 | 15 | 90 | 86 (5) | 92 (5) | 2.1 | 4.7 |
| escBEACOPP ×6 | 711 | 34 (18-60) | 85 | 15 | 94 | 90 (5) | 95 (5) | 0.8 | 2.4 | |
| BEACOPP-14 ×8 | 710 | 33 (18-60) | 85 | 17 | 92 | 86 (5) | 95 (5) | 0.8 | 3.1 | |
| GHSG HD 1810 | escBEACOPP ×2, if PET-2+, randomization escBEACOPP ×4-6 | 219 | 30 (18-60) | 78 | 13 | 97 | 91 (3) | 97 (3) | <1 | 3 |
| escBEACOPP ×2, if PET-2+, randomization escBEACOPP+R ×4-6 | 220 | 29 (18-60) | 75 | 22 | 93 | 93 (3) | 94 (3) | 1 | 1 | |
| EORTC 20012 Intergroup trial5 | ABVD ×8 | 275 | 35 (16-67) | 100 | 100* | 83 | 73 (4) | 87 (4) | 3.3 | 3 |
| escBEACOPP ×4, then BEACOPP ×4 | 274 | 35 (16-61) | 100 | 100* | 83 (4) | 90 (4) | 2.2 | 4 | ||
| RATHL6 | ABVD ×2, if PET-2−, randomization to ABVD ×4 | 470 | 32 (18-79) | 59 | 16 | 100 | 86 (3) | 97 (3) | 0.9 | 2.8 |
| ABVD ×2, if PET-2−, randomization to ABVD ×4 | 465 | 33 (18-76) | 58 | 14 | 100 | 84 (3) | 98 (3) | 0 | 2.4 | |
| ABVD ×2, if PET-2+, for escBEACOPP ×4 or BEACOPP-14 ×6 | 172 | 32 (18-70) | 58 | 30 | 74.4 | 66 (3) | 88 (3) | 2.3 | 1.7 | |
| US Intergroup SWOG trial SO81649 | ABVD ×2, if PET-2−, for ABVD ×4 | 370 | 32 (18-60) | 100 | 51 | 96 | 82 (2) | NA | <1 | 1 |
| ABVD ×2, if PET-2+, for escBEACOPP ×6 | 55 | 55 | 64 (2) | NA | 4 | 6.1 | ||||
| AHL2011 Lysa study52 | escBEACOPP ×2, if PET−, for ABVD ×4 | 319 | 30 (16-60) | 88 | 58* | NA | 88 (2) | NA | <1 | NA |
| escBEACOPP ×2, if PET+, for escBEACOPP ×4 | 49 | NA | NA | 8 | NA | |||||
| escBEACOPP ×6 (no PET adaptation) | 401 | NA | 92 (2) | NA | NA |
| Trial . | Regimen . | n . | Mean/median age, y (range) . | Stage III/IV, % . | IPS ≥4, % . | CR/Cru, % . | PFS, % (y) . | OS, % (y) . | TRM, % . | Secondary malignancies, % . |
|---|---|---|---|---|---|---|---|---|---|---|
| HD200036 | ABVD ×6 | 99 | 32 (NA) | 67 | 30* | 84 | 69 (10) | 85 (10) | 0 | 1 |
| escBEACOPP ×4, then BEACOPP ×2 | 98 | 29 (NA) | 69 | 43* | 91 | 75 (10) | 84 (10) | 2 | 6 | |
| COPPEBVCAD ×6 | 98 | 33 (NA) | 71 | 44* | 83 | 76 (10) | 86 (10) | 0 | 6 | |
| GHSG HD1235 | escBEACOPP ×8 +RT | 392 | 36 (16-65) | 83 | 15 | 93 | 89 (5) | 92 (5) | 2 | 3.6 |
| escBEACOPP ×8 −RT | 395 | 35 (16-65) | 84 | 18 | 93 | 87 (5) | 91 (5) | 2.8 | 2.3 | |
| escBEACOPP ×4, then BEACOPP ×4 +RT | 393 | 36 (16-65) | 83 | 19 | 92 | 87 (5) | 91 (5) | 4.3 | 2.5 | |
| escBEACOPP ×4, then BEACOPP ×4 −RT | 394 | 35 (16-65) | 85 | 15 | 90 | 84 (5) | 90 (5) | 2.5 | 0.8 | |
| Viviani et al37 | ABVD ×6-8, then re-induction and HDT/ASCT if less than CR or PD | 168 | NR | NR | 53* | 76 | 73 (7) | 84 (7) | 1 | 1 |
| escBEACOPP ×4, then BEACOPP ×4 then re-induction and HDT/ASCT if less than CR or PD | 163 | NR | NR | 53* | 81 | 85 (7) | 89 (7) | 2 | 1 | |
| GHSG HD154 | escBEACOPP ×8 | 705 | 33 (18-60) | 83 | 15 | 90 | 86 (5) | 92 (5) | 2.1 | 4.7 |
| escBEACOPP ×6 | 711 | 34 (18-60) | 85 | 15 | 94 | 90 (5) | 95 (5) | 0.8 | 2.4 | |
| BEACOPP-14 ×8 | 710 | 33 (18-60) | 85 | 17 | 92 | 86 (5) | 95 (5) | 0.8 | 3.1 | |
| GHSG HD 1810 | escBEACOPP ×2, if PET-2+, randomization escBEACOPP ×4-6 | 219 | 30 (18-60) | 78 | 13 | 97 | 91 (3) | 97 (3) | <1 | 3 |
| escBEACOPP ×2, if PET-2+, randomization escBEACOPP+R ×4-6 | 220 | 29 (18-60) | 75 | 22 | 93 | 93 (3) | 94 (3) | 1 | 1 | |
| EORTC 20012 Intergroup trial5 | ABVD ×8 | 275 | 35 (16-67) | 100 | 100* | 83 | 73 (4) | 87 (4) | 3.3 | 3 |
| escBEACOPP ×4, then BEACOPP ×4 | 274 | 35 (16-61) | 100 | 100* | 83 (4) | 90 (4) | 2.2 | 4 | ||
| RATHL6 | ABVD ×2, if PET-2−, randomization to ABVD ×4 | 470 | 32 (18-79) | 59 | 16 | 100 | 86 (3) | 97 (3) | 0.9 | 2.8 |
| ABVD ×2, if PET-2−, randomization to ABVD ×4 | 465 | 33 (18-76) | 58 | 14 | 100 | 84 (3) | 98 (3) | 0 | 2.4 | |
| ABVD ×2, if PET-2+, for escBEACOPP ×4 or BEACOPP-14 ×6 | 172 | 32 (18-70) | 58 | 30 | 74.4 | 66 (3) | 88 (3) | 2.3 | 1.7 | |
| US Intergroup SWOG trial SO81649 | ABVD ×2, if PET-2−, for ABVD ×4 | 370 | 32 (18-60) | 100 | 51 | 96 | 82 (2) | NA | <1 | 1 |
| ABVD ×2, if PET-2+, for escBEACOPP ×6 | 55 | 55 | 64 (2) | NA | 4 | 6.1 | ||||
| AHL2011 Lysa study52 | escBEACOPP ×2, if PET−, for ABVD ×4 | 319 | 30 (16-60) | 88 | 58* | NA | 88 (2) | NA | <1 | NA |
| escBEACOPP ×2, if PET+, for escBEACOPP ×4 | 49 | NA | NA | 8 | NA | |||||
| escBEACOPP ×6 (no PET adaptation) | 401 | NA | 92 (2) | NA | NA |
ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ASCT, autologous stem cell transplantation; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; COPPEBVCAD, cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, bleomycin; CR, complete response; Cru, unconfirmed complete response; EORTC, European Organisation for Research and Treatment of Cancer; escBEACOPP, escalated BEACOPP; GHSG, German Hodgkin Study Group; HDT, high-dose therapy; IPS, International Prognostic Score; NA, not available; NR, not reached; OS, overall survival; PD, progressive disease; PET, positron emission tomography; PFS, progression-free survival; RATHL, Response-Adjusted Therapy for Hodgkin Lymphoma; RT, radiotherapy; TRM, treatment-related mortality.
IPS ≥ 3.